-
Jan 16, 2025 | 
agcbio.com | AGC Biologics
Today, we announced a development and manufacturing services agreement with Adaptimmune, a company working to redefine the treatment of solid tumor cancers with cell therapy. The CDMO is manufacturing the lentiviral vector used to produce letetresgene autoleucel (“lete-cel”), an engineered TCR T-cell therapy targeting the solid tumor antigen NY-ESO-1.
-
Jan 9, 2025 | 
agcbio.com | AGC Biologics
AGC Biologics’ Cell and Gene Center of Excellence expands exosome work with new project. Today, we announced a partnership with Pandorum to produce their flagship product Kuragenx—the 'liquid cornea'—a combination biologic.
-
Jan 9, 2025 | 
agcbio.com | AGC Biologics
AGC Biologics’ Cell and Gene Center of Excellence expands exosome work with new project. Today, we announced a partnership with Pandorum to produce their flagship product Kuragenx—the 'liquid cornea'—a combination biologic.
-
Dec 11, 2024 | 
agcbio.com | AGC Biologics
CDMO’s Cell and Gene Center of Excellence Achieves fifth commercial viral vector product approval, and second overall from FDA in 2024Today, we announced that the U.S. Food and Drug Administration (FDA) approved our Milan Cell and Gene Center of Excellence site for commercial manufacturing of lentiviral vectors for Autolus Therapeutics’ AUCATZYL® (obecabtagene autoleucel – obe-cel).
-
Oct 28, 2024 | 
accesswire.com | AGC Biologics
Under new leadership, AGC Biologics will be "Your friendly CDMO expert" SEATTLE, WA / ACCESSWIRE / October 28, 2024 / AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Alberto Santagostino to Chief Executive Officer and President of AGC Biologics, effective November 1st. Alberto has had a distinguished career in biotech, pharma and managing large-scale global CDMO operations.
-
Oct 28, 2024 | 
finance.yahoo.com | AGC Biologics
In case you haven't noticed, the bulls are very much in control on Wall Street. The mature stock-driven Dow Jones Industrial Average, benchmark S&P 500, and growth-propelled Nasdaq Composite, have all soared to multiple record-closing highs in 2024.
-
Oct 17, 2024 | 
accesswire.com | AGC Biologics
Q1 2024 inspection results in three new commercial approvals for manufacturing AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the U.S. Food and Drug Administration (FDA)'s approval of a third Biologics License Applications (BLA) from the March 2024 inspection of the company's Seattle facility.
-
Oct 17, 2024 | 
agcbio.com | AGC Biologics
Q1 2024 inspection results in three new commercial approvals for manufacturing Today, we announced the U.S. Food and Drug Administration (FDA)’s approval of a third Biologics License Applications (BLA) from the March 2024 inspection at our Seattle facility. The closure of this inspection and final BLA approval resulted in each of the three commercial products evaluated being approved for commercial production – a regulatory compliance and quality milestone for the site.
-
Oct 10, 2024 | 
finance.yahoo.com | AGC Biologics
COPENHAGEN, DENMARK / ACCESSWIRE / October 10, 2024 / AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today the successful completion of the final milestone at its new manufacturing building at its Copenhagen site. The site received authorization and a license to begin production from the Danish Medicines Agency for its new four-story 19,000 m² manufacturing building in September, allowing it to begin official operations.
-
Oct 9, 2024 | 
agcbio.com | AGC Biologics
Today, we announced the successful completion of the final milestone at our new manufacturing building at our Copenhagen site. The site received authorization and a license to begin production from the Danish Medicines Agency for its new four-story 19,000 m² manufacturing building in September, allowing it to begin official operations. AGC Biologics started production on our first project at the new building shortly after approval, a phase II/III clinical project.
